AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NASHVILLE, TENN. -- Oculorespiratory syndrome is a newly recognized--but apparently not new--adverse event following influenza immunization, Dr. Nooshin Ahmadipour said at the National Immunization Conference sponsored by the Centers for Disease Control and Prevention.
During the 2000-2001 influenza season, Canadian health authorities received an unusually large number of reports of ocular and respiratory signs and symptoms following influenza immunization. Dubbed oculorespiratory syndrome (ORS), the previously unrecognized and mostly mild phenomenon was linked to one particular manufacturer's vaccine that contained a high level of unsplit virion (Can. Commun. Dis. Rep. 26[23]:201-02, 2000).
But even after the implicated vaccine was reformulated, a smaller number of cases continued to be reported after influenza immunization with all vaccine lots in subsequent seasons in Canada, and the syndrome has since been documented in the United States as well. Enhanced surveillance and publicity in Canada about ORS probably led to increased reporting of the syndrome starting in the 2000-2001 season, said Dr. Ahmadipour, an epidemiologist with Health Canada, Ottawa, Ontario.
In 2001, ORS was defined as one or more of the following symptoms within 24 hours of influenza vaccination: Bilateral red eyes, cough, wheezing, chest tightness, sore throat, difficulty breathing, dysphagia, hoarseness, and/or facial swelling; no limit was set on symptom duration.
For the 2000-2001 season, 1,508 cases of ORS were reported in Canada, or 124 per million doses distributed. In 2001-2002, the number dropped to 965 (103 per million), and in 2002-2003, it fell to 523 (50 per million). The most common ORS symptom was red eyes, reported at a rate of 28 per million in 2002-2003, followed by cough (23 per million), sore throat (19 per million), and facial swelling (18 per million).
Before 2000, reported rates of cases meeting the 2001 ORS definition were two per million in 1998-1999 and five per million in 1999-2000. In comparison, reported rates of ...
Source: HighBeam Research, Oculorespiratory syndrome: adverse event from flu vaccine...